Vol 78, No 7-8 (2020)
Expert opinion
Published online: 2020-08-12

open access

Page views 901
Article views/downloads 853
Get Citation

Connect on Social Media

Connect on Social Media

Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society

Agnieszka Tycińska, Marek Gierlotka, Jarosław Bugajski, Marek Deja, Rafał Depukat, Marcin Gruchała, Grzegorz Grześk, Jarosław D. Kasprzak, Jacek Kubica, Ewa Kucewicz-Czech, Przemysław Leszek, Joanna Płonka, Bożena Sobkowicz, Ewa Straburzyńska-Migaj, Katarzyna Wilk, Barbara Zawiślak, Robert Zymliński, Janina Stępińska
Pubmed: 32788567
Kardiol Pol 2020;78(7-8):825-834.


ABSTRACT Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium sensitivity of cardiomyocytes, acts as a vasodilator due to the opening of potassium channels, and has a cardioprotective effect. Levosimendan is mainly used in the treatment of acute decompensated heart failure (class IIb recommendation according to the European Society of Cardiology guidelines). However, numerous clinical trials indicate the validity of repeated infusions of levosimendan in patients with stable heart failure as a bridge therapy to heart transplantation, and in patients with accompanying right ventricular heart failure and pulmonary hypertension. Due to the complex mechanism of action, including the cardioprotective and anti­ ­aggregating effect, the use of levosimendan may be particularly beneficial in acute coronary syndromes, preventing the occurrence of acute heart failure. There are data indicating that levosimendan administered prior to cardiac surgery may improve outcomes in patients with severely impaired left ventricular function. The multidirectional mechanism of action also affects other organs and systems. The positive effect of levosimendan in the treatment of cardiorenal and cardiohepatic syndromes has been shown. It has a safe and predictable profile of action, does not induce tolerance, and shows no adverse effects affecting patients survival or prognosis. However, with inconclusive results of previous studies, there is aneed for awell-designed multicenter randomized placebo­‑controlled study, including an adequately large group of outpatients with chronic advanced systolic heart failure.

Article available in PDF format

View PDF Download PDF file

Polish Heart Journal (Kardiologia Polska)